BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Nikang Therapeutics Inc.

Headquarters: Wilmington, DE, United States
Year Founded: 2017
Status: Private

BioCentury | Apr 18, 2024
Product Development

CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?

AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
BioCentury | Jan 5, 2024
Management Tracks

Friedman succeeding Hoos at Scorpion

Plus: 4DMT hires Noriyuki Kasahara as CSO, and updates from SV, Omega, AbbVie Ventures, Nikang, Immunome, Wugen, Zevra and Quris
BioCentury | Jun 11, 2021
Management Tracks

Slavitt steps down from Biden’s pandemic response team; plus Ocugen, Flexion, Syros, Monte Rosa and more

Andy Slavitt has stepped down as senior adviser to the Biden administration’s coronavirus pandemic response team; the special government employee position limits service time to 130 days.
BioCentury | May 26, 2021
Finance

Building on discovery platform and early deals, CBC-backed NiKang adds $200M in crossover series C round

With backing from high-profile crossover investors, four-year-old company taking wholly-owned HIF2A program into clinic
BioCentury | Apr 24, 2020
Product Development

April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda

Jakafi meets in Phase III for GvHD; low dose Avastin for retinopathy of prematurity
Items per page:
1 - 6 of 6
Username